Amgen, SoftBank and Alexandria Real Estate Equities helped the neurodegenerative disease drug developer publicly launch with $500m in funding.
Neumora Therapeutics, a US-based developer of brain disease treatments, has collected over $500m in a series A round that included $100m from pharmaceutical firm Amgen. Internet and telecommunications conglomerate SoftBank’s Vision Fund 2 also took part in the round, as did life sciences real estate investment trust Alexandria Real Estate Equities, through venture capital arm…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.